135 related articles for article (PubMed ID: 2640153)
1. Further characterization of drug-sensitivity and cross-resistance profiles of cloned cell lines of Adriamycin-sensitive and -resistant P388 leukemia.
Seneviratne C; Goldenberg GJ
Cancer Commun; 1989; 1(1):21-7. PubMed ID: 2640153
[TBL] [Abstract][Full Text] [Related]
2. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
[TBL] [Abstract][Full Text] [Related]
3. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Goldenberg GJ; Wang H; Blair GW
Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.
Nakamura K; Sugumi H; Yamaguchi A; Uenaka T; Kotake Y; Okada T; Kamata J; Niijima J; Nagasu T; Koyanagi N; Yoshino H; Kitoh K; Yoshimatsu K
Mol Cancer Ther; 2002 Jan; 1(3):169-75. PubMed ID: 12467211
[TBL] [Abstract][Full Text] [Related]
6. Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha.
McPherson JP; Deffie AM; Jones NR; Brown GA; Deuchars KL; Goldenberg GJ
Anticancer Res; 1997; 17(6D):4243-52. PubMed ID: 9494516
[TBL] [Abstract][Full Text] [Related]
7. Uptake and retention of morpholinyl anthracyclines by adriamycin-sensitive and -resistant P388 cells.
Streeter DG; Johl JS; Gordon GR; Peters JH
Cancer Chemother Pharmacol; 1986; 16(3):247-52. PubMed ID: 3457646
[TBL] [Abstract][Full Text] [Related]
8. In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone.
Gutierrez PL; Wilder PJ; Biswal N
Cancer Commun; 1989; 1(3):181-90. PubMed ID: 2576972
[TBL] [Abstract][Full Text] [Related]
9. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines.
Dong J; Naito M; Tatsuta T; Seimiya H; Johdo O; Tsuruo T
Oncol Res; 1995; 7(5):245-52. PubMed ID: 8534930
[TBL] [Abstract][Full Text] [Related]
10. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M
Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108
[TBL] [Abstract][Full Text] [Related]
11. Resistance and cross-resistance of cultured leukemia P388 cells to vincristine, adriamycin, adriamycin analogs, and actinomycin D.
Wilkoff LJ; Dulmadge EA
J Natl Cancer Inst; 1978 Dec; 61(6):1521-4. PubMed ID: 281559
[TBL] [Abstract][Full Text] [Related]
12. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines.
Deffie AM; Batra JK; Goldenberg GJ
Cancer Res; 1989 Jan; 49(1):58-62. PubMed ID: 2535693
[TBL] [Abstract][Full Text] [Related]
13. Enhanced efflux of actinomycin D, vincristine, and vinblastine in adriamycin-resistant subline of P388 leukemia.
Inaba M; Sakurai Y
Cancer Lett; 1979 Dec; 8(2):111-5. PubMed ID: 555868
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone.
Kamath N; Grabowski D; Ford J; Kerrigan D; Pommier Y; Ganapathi R
Biochem Pharmacol; 1992 Sep; 44(5):937-45. PubMed ID: 1356339
[TBL] [Abstract][Full Text] [Related]
15. Multifactorial resistance to antineoplastic agents in drug-resistant P388 murine leukemia, Chinese hamster ovary, and human HeLa cells, with emphasis on the role of DNA topoisomerase II.
Deffie AM; McPherson JP; Gupta RS; Hedley DW; Goldenberg GJ
Biochem Cell Biol; 1992 May; 70(5):354-64. PubMed ID: 1353968
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of adriamycin-induced cytotoxicity by increasing retention and inhibition of DNA repair in DOX-resistant P388 cell lines with new calcium channel blocker, DMDP.
Bankusli I; Yin MB; Mazzoni A; Abdellah AJ; Rustum YM
Anticancer Res; 1989; 9(3):567-74. PubMed ID: 2764503
[TBL] [Abstract][Full Text] [Related]
17. Comparative cytotoxicities of various morpholinyl anthracyclines.
Streeter DG; Taylor DL; Acton EM; Peters JH
Cancer Chemother Pharmacol; 1985; 14(2):160-4. PubMed ID: 3971481
[TBL] [Abstract][Full Text] [Related]
18. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
19. Etoposide-resistant human colon and lung adenocarcinoma cell lines exhibit sensitivity to homoharringtonine.
Wilkoff LJ; Dulmadge EA; Vasanthakumar G; Donahue JP
Cancer Chemother Pharmacol; 1993; 33(2):149-53. PubMed ID: 8261574
[TBL] [Abstract][Full Text] [Related]
20. Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro.
Etievant C; Barret JM; Kruczynski A; Perrin D; Hill BT
Invest New Drugs; 1998; 16(1):3-17. PubMed ID: 9740539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]